medicines patent pool
LinkedIn YouTube Bluesky X
Search
EN / FR
Ethics Portal
  • Who We Are
      • Who We Are
      • About Us
      • Business Model
      • Our Strategy 2026-2030
      • Statutes, By-Laws & Policies
      • Governance & Team
      • Annual Reports
      • Contact Us
      • Work with us
      • Working at MPP
      • Careers & RFPs
  • What We Do
      • What We Do
      • Licensing for Public Health
      • mRNA Technology Transfer Programme
      • Disease Areas
      • Addressing Children’s Needs
      • Prioritising Medicines for Licensing
      • Long-Acting Therapeutics
      • Focus areas
      • Biotherapeutics
      • Local and Regional Manufacturing
      • Pandemic Preparedness and Response
      • Upstream Access
      • Technology Transfer
      • Digital Information Tools
      • AccessPaL
      • LAPaL
      • MedsPaL
  • Progress & Impact
      • Progress
        and Impact
      • Prioritisation
      • Agreements with Innovators
      • AccessPaL
      • Impact
  • News & Publications
      • News
        & Publications
      • News, Events & Press Releases
      • Messages from the Executive Director & the Team
      • MPP in the Media
      • MPP Publications
      • Related Publications
      • Newsletters & Updates
  • Partners
      • Partners
      • Partnering with MPP
      • How to grant or obtain a licence
      • Funders
      • Our Stories
      • Voices from Friends of MPP
      • The DTG story
  • Support us
EN / FR
Ethics Portal
Search
Partners » Our Stories » Voices from Friends of MPP
MPP and Penta Foundation working together for greater access to RSV prevention and treatment medicines in low- and middle-income countries

Latest Voices from Friends of MPP

MPP and Penta Foundation working together for greater access to RSV prevention and treatment medicines in low- and middle-income countries

In the second of our two stories focusing on RSV, MPP is marking World Children’s Day 2026 by examining the possible moves towards RSV prevention and treatment options in low-and middle-income countries. MPP is exploring how voluntary licensing and technology transfer could support earlier, more affordable access to new RSV medicines. We speak to Anna […]

20 November 2026

Keyword

Selected Filters:

Loading...
Load More
MPP Logo
  • About Us
  • MedsPaL
  • licences
  • Careers & RFPs
  • Privacy Policy
Follow us
LinkedIn YouTube Bluesky X

Founded & funded by

Unitaid Logo

Other funders

Designed and built by ACW